This non-randomized, single group, open-label study will investigate the mass balance, routes of elimination, pharmacokinetics, and metabolism of a single oral dose of RO5424802 and the pharmacokinetics of a 14C-labeled tracer in healthy volunteers
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
6
Single oral doses followed by IV or oral administration of a 14C-labeled tracer
Unnamed facility
Zuidlaren, Netherlands
Elimination: Amount of drug excreted in urine/feces over the study period
Time frame: Days 11 to 15
Pharmacokinetics: Bioavailability (Area under the plasma concentration-time curve [AUC]) after administration of RO5424802
Time frame: Days 1 to 25
Safety: Incidence of adverse events
Time frame: Days 1 to 25
Pharmacokinetics: Metabolite identification in plasma, urine, and feces.
Time frame: Days 11 to 25
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.